Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2491 to 2505 of 8213 results

  1. Ondansetron for treating alcohol-use disorder [ID6341]

    Awaiting development Reference number: GID-TA11375 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Aprocitentan for treating resistant hypertension [TSID10395]

    Awaiting development Reference number: GID-TA11459 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Abatacept for treating active idiopathic inflammatory myopathies [TSID10095]

    Awaiting development Reference number: GID-TA10993 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable [ID6272]

    Topic prioritisation

    Health technology evaluations
    Topic prioritisation

  5. NVK-002 for treating myopia in people 3 to 17 years [TSID11961]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia [TSID12043]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Linaclotide acetate for treating Chronic idiopathic constipation [TSID12005]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Eszopiclone for treating insomnia [TSID12020]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia [TSID12043]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. IgPro20 for treating dermatomyositis [TSID12014]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Basal insulin icodec–semaglutide for treating type 2 diabetes inadequately controlled with daily basal insulin [TSID11940]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Subcutaneous amivantamab for treating advanced non-small-cell lung cancer with EGFR mutations [TSID12011]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Olorofim for treating invasive fungal infections in people 16 years and over [TSID11983]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years [TSID12002]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Secukinumab biosimilar for treating plaque psoriasis [TSID11992]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation